EPISODE · Mar 10, 2026 · 1 MIN
Ibrutinib With Immunochemotherapy/ASCT Improves MCL Survival
from TheBrief.Health · host TheBrief.Health
Adding ibrutinib to frontline therapy improves failure-free survival in younger mantle cell lymphoma patients and may reduce routine transplant use, though infection and blood toxicity risks increase.
What this episode covers
Adding ibrutinib to frontline therapy improves failure-free survival in younger mantle cell lymphoma patients and may reduce routine transplant use, though infection and blood toxicity risks increase.
NOW PLAYING
Ibrutinib With Immunochemotherapy/ASCT Improves MCL Survival
No transcript for this episode yet
Similar Episodes
Apr 21, 2026 ·13m
Apr 19, 2026 ·16m
Apr 17, 2026 ·13m
Apr 13, 2026 ·11m
Apr 11, 2026 ·16m